Bladder-sparing trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: A systematic review and meta-analysis of comparative studies
{"title":"Bladder-sparing trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: A systematic review and meta-analysis of comparative studies","authors":"","doi":"10.36879/jcst.20.000115","DOIUrl":null,"url":null,"abstract":"Objective: To compare oncologic outcomes between patients with muscle-invasive bladder cancer who were treated with radical cystectomy (RC) or\ntrimodal therapy (TMT).\nMaterials and Methods: The primary sources were the PubMed, Embase, and Cochrane Library electronic databases. Studies published between\nJune 1990 and July 2017 that evaluated combination bladder-sparing surgery for a bladder tumour with radiotherapy (RT) and chemotherapy\ncompared with RC surgery alone for MIBC were included. Published data were extracted and used to calculate the 5-year overall survival rates. The\nsecondary efficacy endpoints were disease-free survival and local and distant recurrence.\nResults: Nine studies incorporating 15,160 cases were included in the final analysis. Pooled data from 8 studies that assessed overall survival rates\nfor 15,089 patients showed no significant differences in this metric between the TMT and RC groups (HR: 1.27; 95% CI, 0.98-1.63; P=0.066). No\nsignificant differences were found between TMT and RC in the subgroup analyses according to the lymph node stage (Nx), age and physiclal status\n(PS) stage, but differences were found for patients with node-negative disease (HR: 1.36; 95% CI, 1.02-1.81; P=0.036). Disease-free survival and\nlocal and distant recurrence did not differ significantly between the techniques.\nConclusion: RC seems to be suitable for node-negative disease patients. TMT yielded survival outcomes similar to those of patients who underwent\nRC. Given the inherent limitations of the included studies, future well-designed RCTs are needed to confirm and update the findings of this analysis.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"497 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer science and clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36879/jcst.20.000115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To compare oncologic outcomes between patients with muscle-invasive bladder cancer who were treated with radical cystectomy (RC) or
trimodal therapy (TMT).
Materials and Methods: The primary sources were the PubMed, Embase, and Cochrane Library electronic databases. Studies published between
June 1990 and July 2017 that evaluated combination bladder-sparing surgery for a bladder tumour with radiotherapy (RT) and chemotherapy
compared with RC surgery alone for MIBC were included. Published data were extracted and used to calculate the 5-year overall survival rates. The
secondary efficacy endpoints were disease-free survival and local and distant recurrence.
Results: Nine studies incorporating 15,160 cases were included in the final analysis. Pooled data from 8 studies that assessed overall survival rates
for 15,089 patients showed no significant differences in this metric between the TMT and RC groups (HR: 1.27; 95% CI, 0.98-1.63; P=0.066). No
significant differences were found between TMT and RC in the subgroup analyses according to the lymph node stage (Nx), age and physiclal status
(PS) stage, but differences were found for patients with node-negative disease (HR: 1.36; 95% CI, 1.02-1.81; P=0.036). Disease-free survival and
local and distant recurrence did not differ significantly between the techniques.
Conclusion: RC seems to be suitable for node-negative disease patients. TMT yielded survival outcomes similar to those of patients who underwent
RC. Given the inherent limitations of the included studies, future well-designed RCTs are needed to confirm and update the findings of this analysis.